Press Release

RNAi Technology Market to Grow with a CAGR of 9.89% through 2028

Rising advancements in drug discovery and development are expected to drive the Global RNAi Technology Market growth in the forecast period, 2024-2028.

 

 According to TechSci Research report, “RNAi Technology Market – Global Industry Size, Share, Trends, Competition Forecast & Opportunities, 2028”, the Global RNAi Technology Market stood at USD 1.08 billion in 2022 and is anticipated to grow with a CAGR of 9.89% in the forecast period, 2024-2028.

The Global RNAi Technology Market is a thriving and dynamic industry that encompasses various sectors, from healthcare to agriculture and research. With its transformative potential in gene regulation and therapy, RNAi technology is poised to drive innovation and address some of the most pressing challenges in science and medicine. As research and development efforts continue to advance, this market is likely to witness sustained growth and innovation in the coming years. One of the primary drivers fueling the RNAi technology market is the increasing demand for RNAi-based therapeutics. RNAi offers a unique approach to target specific genes responsible for various diseases, including cancer, viral infections, and genetic disorders. This precision medicine approach holds great promise for developing highly effective and targeted therapies. Pharmaceutical companies are actively investing in RNAi research and clinical trials to develop a new generation of drugs. The global burden of chronic diseases, such as cancer, diabetes, and neurodegenerative disorders, continues to rise. RNAi technology's ability to selectively silence disease-associated genes has the potential to revolutionize the treatment of these conditions. With an aging population and changing lifestyles contributing to the prevalence of chronic diseases, the demand for innovative therapies that target the underlying genetic causes is expected to drive the RNAi technology market's growth.

Efficient and safe delivery of RNAi molecules to target cells has been a major challenge in the field. However, significant advancements in delivery systems have been made, enabling the effective administration of RNAi therapeutics. Lipid nanoparticles, viral vectors, and nanoparticle-based carriers have shown promise in enhancing the delivery of RNAi molecules to specific tissues and cells. These innovations have opened up new avenues for the development of RNAi-based drugs and have contributed to the market's expansion. The RNAi technology market benefits from a robust ecosystem of research and development activities. Academic institutions, biotechnology companies, and research organizations are actively exploring the potential of RNAi in various applications, including functional genomics, target validation, and drug discovery. This continuous exploration and innovation contribute to the growth of the RNAi technology market by expanding its scope and applications.

 

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Global RNAi Technology Market.

 

RNAi technology has become an indispensable tool in functional genomics and drug discovery. Researchers are using RNAi to investigate gene functions, validate drug targets, and identify potential therapeutic candidates. The ability to selectively silence specific genes has accelerated the pace of drug development by enabling a more precise understanding of disease mechanisms and pathways.

The Global RNAi Technology Market is segmented into Type, Application, End User, regional distribution, and company.

Based on the Type, the Small interfering RNA (siRNA) segment emerged as the dominant segment in the global market for Global RNAi Technology Market in 2022. siRNAs are designed to specifically target and silence individual genes with a high degree of precision. This specificity is crucial in therapeutic applications and functional genomics, where accurate gene modulation is essential. siRNAs have demonstrated significant therapeutic potential for treating various diseases, including hereditary transthyretin amyloidosis, by selectively inhibiting disease-causing genes. This has led to numerous clinical trials and FDA-approved siRNA-based drugs, such as Onpattro®.Also, Advances in delivery systems, such as lipid nanoparticles, have improved the effective delivery of siRNAs to target cells and tissues, overcoming a longstanding challenge in RNAi technology.

Based on the Application, the Therapeutics segment emerged as the dominant player in the global market for Global RNAi Technology Market in 2022.  Chronic diseases such as cancer, diabetes, cardiovascular disorders, and neurodegenerative conditions are on the rise worldwide. RNAi-based therapeutics hold great promise in treating these diseases by specifically targeting the genetic drivers of these conditions. RNA interference (RNAi) technology has made remarkable strides in the development of RNAi-based therapeutics. The successful FDA approval of drugs like Onpattro® for hereditary transthyretin amyloidosis demonstrates the clinical potential of RNAi-based therapies. The global healthcare landscape is increasingly emphasizing precision medicine, which tailors treatments to individual patients based on their genetic makeup. RNAi technology aligns perfectly with this approach, offering precise and targeted therapies for a wide range of diseases. Moreover, RNAi technology allows for the development of customized treatments by targeting disease-associated genes and pathways. This personalization of therapies can result in more effective treatments with fewer side effects.

Based on the End User, the Research and Academic Laboratories segment emerged as the dominant player in the global market for Global RNAi Technology Market in 2022 . RNA interference (RNAi) technology has its roots in research and academia, where it was first discovered and developed. Academic institutions and research laboratories have been at the forefront of RNAi research, driving innovation and expanding our understanding of gene regulation. RNAi is an essential tool in functional genomics, allowing researchers to investigate the function of specific genes and pathways. Academic laboratories heavily rely on RNAi to conduct experiments, validate drug targets, and advance scientific knowledge.

North America emerged as the dominant player in the global RNAi Technology Market   in 2022, holding the largest market share. This is on account of the advanced healthcare infrastructure, strong biotechnology and pharmaceutical sector and government support and funding of the region. Both the U.S. and Canadian governments allocate significant funding for life sciences and biotechnology research. These investments support RNAi research and its applications in various fields, including healthcare and agriculture.

 

Major companies operating in Global RNAi Technology Market are:

  • Alnylam Pharmaceuticals, Inc
  • Ionis Pharmaceuticals, Inc.
  • Atalanta Therapeutics
  • Phio Pharmaceuticals
  • Benitec Biopharma
  • Novartis AG
  • AstraZeneca
  • Silence Therapeutics
  • Arbutus Biopharma
  • Sylentis S.A.

 

Download Free Sample Report

Customers can also request for 10% free customization on this report.

 

 “The Global RNAi Technology Market is poised for substantial growth in the coming years, driven by several key factors. Firstly, the increasing prevalence of chronic diseases, such as cancer, diabetes, and neurodegenerative disorders, is fueling the demand for precision medicine solutions, making RNAi-based therapies more attractive. Furthermore, advancements in delivery systems and the ability to mitigate off-target effects are enhancing the safety and efficacy of RNAi technology, encouraging its adoption in clinical settings. Additionally, the convergence of RNAi technology with precision medicine and personalized therapies aligns with the evolving healthcare paradigm, where treatments are tailored to individual patient profiles. The expanding role of RNAi in functional genomics and drug discovery is accelerating research efforts and identifying novel drug targets. Collaborations, government funding, and intellectual property management are fostering innovation, while the expansion of RNAi technology into agriculture for crop protection is creating new market opportunities.” said Mr. Karan Chechi, Research Director with TechSci Research, a research-based management consulting firm.

RNAi Technology Market   - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Type (Micro RNA, Small interfering RNA, Others), By Application (Treatment Type, Therapeutics, Drug Delivery, Agriculture, Others), By End User (Research and Academic Laboratories, Diagnostic Laboratories, Others) By Region and Competition”, has evaluated the future growth potential of Global RNAi Technology Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global RNAi Technology Market.

 

Contact

Mr. Ken Mathews

708 Third Avenue,

Manhattan, NY,

New York 10017

Tel: +1-646-360-1656

Email: [email protected]

Website: www.techsciresearch.com

Relevant News